VIP

Research Phase

Vasoactive Intestinal Peptide

Aliases
Vasoactive Intestinal Polypeptide, Aviptadil
Administration
Intravenous infusion (studied), Subcutaneous injection (research)

Timing

A general projection of what people report noticing over time, based on the known mechanism and reported use patterns. It is not a guarantee and individual experience varies considerably.

  1. 1

    1–2 Weeks

    Given its extremely short natural half-life, individual doses act within minutes; this window reflects the first days of a research or trial protocol rather than a gradual buildup.

  2. 2

    3–4 Weeks

    Continued dosing in trial contexts is generally required before broader anti-inflammatory trends are assessed.

  3. 3

    5–7 Weeks

    No well-established human timeline exists to reference outside specific trial protocols.

  4. 4

    8–10 Weeks

    No well-established human timeline exists to reference outside specific trial protocols.

  5. 5

    11–15 Weeks

    No well-established human timeline exists to reference outside specific trial protocols.

  6. 6

    16–20 Weeks

    No well-established human timeline exists to reference outside specific trial protocols.

  7. 7

    21–24 Weeks

    This duration exceeds most typical research protocols studied to date.

⚠️ Research context only. This is not medical advice and results are not guaranteed.